Elecsys® sFlt-1/PlGF (Preeclampsia)

Short term prediction and aid in diagnosis of preeclampsia

Elecsys® sFlt-1/PlGF (Preeclampsia)

Short term prediction and aid in diagnosis of preeclampsia

Preeclampsia is a serious multi-system complication of pregnancy, occurring in 3 - 5 % of pregnancies, and it is one of the leading causes of maternal and perinatal morbidity and mortality worldwide.1-3

Preeclampsia is defined as new-onset of hypertension and proteinuria after 20 weeks of gestation. The clinical presentation of preeclampsia and subsequent clinical course of the disease can vary tremendously, making prediction, diagnosis and assessment of disease progression difficult.1-3

Angiogenic factors (sFlt-1 and PlGF) are proven to play an important role in the pathogenesis of preeclampsia and their concentrations in maternal serum are altered even before the onset of the disease making them a tool for prediction and aid in diagnosis of preeclampsia.1-3

Benefits

In a recent multicentre, prospective study – PROGNOSIS (Prediction of short-term outcome in pregnant women with suspected preeclampsia study) – the Elecsys sFlt-1/PlGF ratio proved to be a helpful tool in ­enabling clinicians to exclude preeclampsia for 1 week with very high confidence, ­reassuring women suspected of having the disease that is safe to go home.4,5

 

  • Elecsys sFlt-1 and PlGF immunoassays for preeclampsia are the first available and approved automated diagnostic tests for fast and easy assessment in a clinical context4,5
  • The measurement of the Elecsys sFlt-1/PlGF ratio is a reliable tool to identify the patients that are at high risk to develop preeclampsia requiring a closer monitoring and to confidently send home patients that are not going to develop the disease4-7
  • Early and precise diagnosis of ­preeclampsia can lead to to effective ­clinical management and improved ­outcome for both mother and child4-7

 

First trimester screening of Preeclampsia

 

The additional value of first trimester screening combined with the value of the sFlt-1/PlGF ratio as an aid in the diagnosis of PE and short term prediction and the prediction of adverse outcomes provides a complete solution for PE throughout pregnancy

 

  • Early-onset PE can be predicted effectively based on screening models including PlGF as one of the components8
  • First trimester screening of PE is important to proceed with prophylactic use of low-dose aspirin9-13
  • Identify women at high risk for PE with an algorithm including PlGF and subsequent administration of Aspirin may prevent preterm PE9-13
Elecsys® sFlt-1/PlGF (Preeclampsia)

Elecsys® sFlt-1

  • Assay time

    18 min

  • Sample material

    Serum

  • Sample volume

    20 μL

  • Measuring range

    10– 85,000 pg/mL

Elecsys® PlGF

  • Assay time

    18 min

  • Sample material

    Serum

  • Sample volume

    50 μL

  • Measuring range

    3 – 10,000 pg/mL

References

 

  1. Verlohren, S., et al. (2012). Am J Obstet Gynecol 206(1), e1-8
  2. Verlohren, S., et al. (2010). Am J Obstet Gynecol 202(161), e1-11
  3. Verlohren, S., et al. (2014). Hypertension 63(2), 346-352
  4. Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324
  5. Zeisler, H., et al. (2016). N Engl J Med 374(1), 13-22
  6. Hund, M., et al. (2015). Hypertens Pregnancy 34(1), 102-115
  7. Klein, E., et al. (2014). PLoS ONE 11(5), e0156013
  8. O’Gorman, N., et al. (2016). Am J Obstet Gynecol. 2016 Jan;214(1):103.e1-103.e12
  9. Tsiakkas A., et al. (2016). Ultrasound Obstet Gynecol 47, 472–477 
  10. Poon, I., et al. (2009). Hypertension 53(5), 812-818;
  11. Poon, L. C., et al. (2014). Prenat Diagn 34(7), 618-627
  12. Akolekar, R., et al. (2011). Prenat Diagn 31, 66-74;
  13. Akolekar, R., et al. (2013). Fetal Diagn Ther 33(1), 8-15